ProQR Therapeutics N.V. filings document a Nasdaq-listed foreign private issuer furnishing Form 6-K current reports for its RNA therapeutics business. The disclosures describe the Axiomer RNA editing platform, ADAR-mediated oligonucleotide design, pipeline programs including AX-0810, AX-2402 and AX-2911, scientific presentations, collaborations, and annual operating and financial results.
The filing record also covers governance and capital-market matters, including annual general meeting notices, agenda materials, proxy forms, proposed articles-of-association amendments, board nominations and board-composition updates. Several Form 6-K reports incorporate company materials by reference into Form F-3 registration statements, linking current business updates with registered securities disclosure.
ProQR Therapeutics N.V. amended prior Form 6-K reports solely to incorporate their information and accompanying exhibits by reference into five Form F-3 registration statements, including related prospectuses, to the extent the material is not superseded by later documents or reports. The amendment does not update or restate the earlier disclosures or reflect events occurring after their original filing dates.
ProQR Therapeutics N.V. (PRQR) announced upcoming presentations on AX-0810, AX-0811 and its Axiomer RNA-editing platform. At The Liver Meeting 2026, two AX-0810 Phase 1 posters are scheduled to cover study design and previously disclosed safety, pharmacokinetic and target-engagement findings; one is a late-breaking poster on proof-of-concept data. A TIDES Europe presentation on November 3 will review previously presented AX-0810 findings and preclinical work on AX-0811.
At a December 9 conference, ProQR plans to present Cohort 3 data and the 12 week follow up from the AX-0810 Phase 1 study, alongside new preclinical proof-of-concept data for AX-0811. AX-0811, an NTCP-targeting RNA-editing oligonucleotide being evaluated in a Phase 1 study in healthy volunteers, has initial data expected in early January 2027. ProQR describes its preclinical findings as showing greater potency and durability.
ProQR Therapeutics N.V. (PRQR) announced Chris Hart, PhD, as Chief Data and AI Officer; Thomas Wolf, PhD, will join its Board as a strategic AI advisor. Hart most recently was Vice President of Data Science and AI/ML at Eli Lilly. Wolf co-founded Hugging Face and serves as its Chief Science Officer. Hart will lead AI strategy across drug discovery and development, while Wolf will advise the Board on technology strategy and scaling AI across Axiomer.
ProQR expects up to 5 clinical data readouts over the coming 12 months across 4 development programs. AX-0811, the first program discovered through the company’s AI-enabled process to enter clinical testing, is on track for target-engagement data from its first two cohorts in early January 2027. AX-2911 is expected to follow into the clinic in coming months; AX-0422 and AX-2911 are progressing toward the clinic.
In humanized models, AX-0811 achieved approximately 60% editing efficiency, around six-fold higher than prior-generation AX-0810, with improved stability. ProQR says AI-enabled discovery reduced the timeline from what had taken three years to approximately three months.
ProQR Therapeutics N.V. (PRQR) reported that the first participant has been dosed in its Phase 1 clinical trial of AX-0811, an AI-discovered investigational RNA editing oligonucleotide designed to modulate NTCP as a potential disease-modifying treatment for cholestatic liver diseases, including biliary atresia. The study in healthy volunteers will assess safety, tolerability, pharmacokinetics and pharmacodynamic biomarkers and builds on prior clinical experience with AX-0810, with initial Phase 1 target engagement data from the first two cohorts expected in early January 2027.
ProQR also plans a virtual Investor and Analyst educational event titled “NTCP Modulation in Biliary Atresia via Liver-Targeted RNA Editing” on September 30, 2026 at 11 a.m. ET, featuring company management and Professor Gideon Hirschfield to review AX-0810 Phase 1 data and outline the clinical development strategy for NTCP modulation in biliary atresia.
ProQR Therapeutics N.V. reported second-quarter and first-half 2026 results and detailed recent financing and pipeline progress. For the quarter ended June 30, 2026, revenue was €8.8 million, up from €3.8 million a year earlier, primarily from its collaboration with Eli Lilly. Net loss for the quarter narrowed to €8.7 million, or €0.08 per share, compared with a loss of €12.2 million, or €0.12 per share, in 2025, as operating expenses grew modestly while revenue more than doubled.
Cash and cash equivalents were €117.1 million at June 30, 2026, up from €92.4 million at December 31, 2025, supported by a June underwritten registered direct offering and concurrent private placement raising gross proceeds of about $59.2 million. Management states this provides funding runway into mid-2028 and supports advancement of its Axiomer RNA editing pipeline, including AX-0810 and AX-0811 for cholestatic liver diseases and earlier-stage programs in MPS I Hurler syndrome and MASH.
ProQR Therapeutics reported second-quarter 2026 results and highlighted clinical validation of its Axiomer™ RNA editing platform. Phase 1 data for AX-0810 in healthy volunteers showed up to 8‑fold increases in total serum bile acids at 6 mg/kg, exceeding the predefined 2‑fold threshold for meaningful NTCP modulation, with a favorable safety profile and an estimated eight-week half-life. A Phase 1 trial of next-generation NTCP candidate AX-0811 is planned pending CTA authorization, with initial data expected by year-end 2026, and multiple additional programs (biliary atresia IIT, AX-0422, AX-2911) targeted to read out in 2027.
Financially, second-quarter 2026 revenue was €8.8 million, up from €3.8 million a year earlier, and net loss narrowed to €8.7 million from €12.2 million. Cash and cash equivalents increased to €117.1 million at June 30, 2026 from €92.4 million at year-end 2025, supported by a $59.2 million equity financing with public investors and Eli Lilly. Equity rose to €79.5 million, and management states this funding provides cash runway into mid‑2028.
ProQR Therapeutics N.V. reports that Chief Executive Officer Daniel Anton de Boer purchased 200,000 Ordinary Shares on 2026-07-31 at $1.7698 per share in a transaction described as a purchase in open market or private transaction, increasing his direct holdings to 500,000 shares. The Rule 10b5-1 trading-plan checkbox was not marked for this transaction.
Aberdeen Group plc and its affiliate abrdn Inc. report beneficial ownership of 8,932,507 Ordinary Shares of ProQR Therapeutics N.V., representing 6.33% of this class of shares. The securities are Ordinary Shares with a nominal value of EUR0.04 per share.
Both Aberdeen Group plc and abrdn Inc. report no sole voting or dispositive power over these shares, but each reports shared voting power and shared dispositive power over 8,932,507 shares. abrdn Inc. beneficially owns the shares on behalf of underlying clients within its corporate group structure.
Eli Lilly and Company reports beneficial ownership of 21,995,880 ordinary shares of ProQR Therapeutics N.V., representing 15.6% of the outstanding class of ordinary shares with a nominal value of 0.04 EUR per share.
Eli Lilly holds sole voting power and sole dispositive power over all 21,995,880 shares and reports no shared voting or dispositive power. The filing is signed by Christopher Anderson, Vice President - Leader of Corporate Securities and Assistant Corporate Secretary.